Trial · NCT00643201
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment | Apixaban | 0.0226 | 95% Confidence Interval 0.0169 to 0.0283 | proportion of participants | |
| Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment | Enoxaparin + Warfarin | 0.0269 | 95% Confidence Interval 0.0208 to 0.0331 | proportion of participants | |
| Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death | Apixaban | 0.0322 | 95% Confidence Interval 0.0254 to 0.0390 | proportion of participants | |
| Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death | Enoxaparin + Warfarin | 0.0395 | 95% Confidence Interval 0.0320 to 0.0469 | proportion of participants | |
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death | Apixaban | 0.0234 | 95% Confidence Interval 0.0176 to 0.0292 | proportion of participants | |
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death | Enoxaparin + Warfarin | 0.0292 | 95% Confidence Interval 0.0228 to 0.0357 | proportion of participants | |
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding | Apixaban | 0.0280 | 95% Confidence Interval 0.0216 to 0.0343 | proportion of participants | |
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding | Enoxaparin + Warfarin | 0.0448 | 95% Confidence Interval 0.0369 to 0.0527 | proportion of participants | |
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding | Apixaban | 0.0699 | 95% Confidence Interval 0.0602 to 0.0797 | proportion of participants | |
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding | Enoxaparin + Warfarin | 0.1261 | 95% Confidence Interval 0.1134 to 0.1387 | proportion of participants | |
| Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period | Apixaban | 0.0084 | 95% Confidence Interval 0.0049 to 0.0119 | proportion of participants | |
| Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period | Enoxaparin + Warfarin | 0.0133 | 95% Confidence Interval 0.0089 to 0.0177 | proportion of participants | |
| Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period | Apixaban | 0.0104 | 95% Confidence Interval 0.0065 to 0.0142 | proportion of participants | |
| Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period | Enoxaparin + Warfarin | 0.0095 | 95% Confidence Interval 0.0058 to 0.0132 | proportion of participants | |
| Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period | Apixaban | 0.0046 | 95% Confidence Interval 0.0020 to 0.0072 | proportion of participants | |
| Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period | Enoxaparin + Warfarin | 0.0061 | 95% Confidence Interval 0.0031 to 0.0091 | proportion of participants | |
| Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period | Apixaban | 0.0058 | 95% Confidence Interval 0.0028 to 0.0087 | proportion of participants | |
| Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period | Enoxaparin + Warfarin | 0.0087 | 95% Confidence Interval 0.0052 to 0.0123 | proportion of participants | |
| Incidence of All-Cause Death During the Intended Treatment Period | Apixaban | 0.0157 | 95% Confidence Interval 0.0109 to 0.0205 | proportion of participants | |
| Incidence of All-Cause Death During the Intended Treatment Period | Enoxaparin + Warfarin | 0.0198 | 95% Confidence Interval 0.0145 to 0.0251 | proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00643201/results